Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Molecular diagnosis of NALP3 mutations and clinical picture resembling Muckle-Wells Syndrome.~* Muckle-Wells Syndrome patients who participated in the CACZ885A2102 study, will have the option to participate in this study upon disease flare~* Muckle-Wells Syndrome patients requiring medical intervention either untreated or treated (i.e. under ACZ885, anakinra, or any other investigational IL-1 blocking therapy).~Exclusion Criteria:~* History of being immunocompromised, including a positive HIV at screening test result.~* No live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.~* History of significant medical conditions, which in the Investigator's opinion would exclude the patient from participating in this trial.~* History of recurrent and/or evidence of active bacterial, fungal, or viral infections.~* Positive tuberculin skin test at 48 to 72 hours after administration at the screening visit or within 2 months prior to the screening visit, according to national guidelines.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part I, Part II-arm1, & Part III (Type: EXPERIMENTAL): None
- Part II - arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).